Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone

• Published in: Kidney international Vol. 52; no. 6; pp. 1561 - 1569
• Main Authors: Nagler, Arnon, Katz, Avi, Aingorn, Helena, Miao, Hua-Quan, Condiotti, Reba, Genina, Olga, Pines, Mark, Vlodavsky, Israel
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.12.1997; Nature Publishing
• Subjects: Animals; Biological and medical sciences; Carbon Radioisotopes; Cell Division - drug effects; Cells, Cultured; Collagen - biosynthesis; Collagen - genetics; Collagen - metabolism; collagen type I; extracellular matrix; Extracellular Matrix - drug effects; Extracellular Matrix - metabolism; Gene Expression - drug effects; Glomerular Mesangium - cytology; Glomerular Mesangium - metabolism; glomerulosclerosis; Medical sciences; Mesangial cells; Pharmacology. Drug treatments; Piperidines; Proline - metabolism; Proline - pharmacology; Protein Synthesis Inhibitors - pharmacology; Quinazolines - pharmacology; Quinazolinones; Rats; Rats, Wistar; Sulfates - metabolism; Sulfates - pharmacology; Tritium; Urinary system; Mesangial cells; collagen type I; glomerulosclerosis; extracellular matrix; Cell proliferation; Cell culture; Proliferative glomerulonephritis; Rat; Mesangial cell; Rodentia; Biological activity; Renal glomerulus; Halofuginone; Prevention; Antiprotozoal agent; Vertebrata; Chemotherapy; Mammalia; Animal; Parasiticid; Cell cycle; Extracellular matrix; Quinolone derivatives

Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Mesangial cell proliferation, increased deposition of collagen, and expansion of the mesangial extracellular matrix (ECM) are key features in the development of mesangioproliferative diseases....